Brazil’s Hypermarcas enjoys strong reception for buy-back
Hypermarcas, the Brazilian pharmaceutical company, will not extend the early bird deadline on the tender offer for its 6.5% senior notes due 2021 after bondholders responded positively to the buy-back offer.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: